4-perfluoroethoxyaniline | 717-85-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-perfluoroethoxyaniline
• 英文别名: 4-(pentafluoroethoxy)aniline；4-(1,1,2,2,2-pentafluoroethoxy)aniline
• CAS: 717-85-1
• 化学式: C₈H₆F₅NO
• mdl: MFCD10686955
• 分子量: 227.134
• InChiKey: MDODMMABKXPUEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-perfluoroethoxyaniline 在 溴 、 溶剂黄146 作用下， 以 丁酮 为溶剂， 反应 45.0h， 生成 3-(2-ethylthioethyl)-2-imino-6-pentafluoroethoxy-benzothiazoline
  参考文献：
  名称：

  Riluzole Series. Synthesis and in Vivo “Antiglutamate” Activity of 6-Substituted-2-benzothiazolamines and 3-Substituted-2-imino-benzothiazolines

  摘要：

  Two series of analogues of riluzole, a blocker of excitatory amino acid mediated neurotransmission, have been synthesized: monosubstituted 2-benzothiazolamines and 3-substituted derivatives. Of all the compounds prepared in the first series, only 2-benzothiazolamines bearing alkyl, polyfluoroalkyl, or polyfluoroalkoxy substituents in the 6-position showed potent anticonvulsant activity against administration of glutamic acid in rats. The most active compounds displaying in vivo "antiglutamate" activity were the 6-OCF3 (riluzole), 6-OCF2CF3, 6-CF3, and 6-CF2CF3 substituted derivatives with ED50 values between 2.5 and 3.2 mg/kg i.p. Among the second series of variously substituted benzothiazolines, compounds as active as riluzole or up to 3 times more potent were identified in two series: benzothiazolines bearing a beta-dialkylaminoethyl moiety and compounds with an alkylthioalkyl chain and their corresponding sulfoxides and sulfones. The most potent derivatives were 2-imino-3-(2-methylthio)- and 2-imino-3-(2-methylsulfinyl)-ethyl-6-trifluoromethoxybenzothiazlines (61 and 64, ED50 = 10 and 1.1 mg/kg i.p., respectively). In addition, intraperitoneal administration of some of the best benzothiazolines protected mice from mortality produced by hypobaric hypoxia.

  DOI：

  10.1021/jm980202u

文献信息

• COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：DODD Stephanie Kay

  公开号：US20130310395A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I): in which Y, Y 1 , R 1 , R 2 , R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y、Y1、R1、R2、R3和R4如发明摘要中所定义；能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括这种化合物的制药制剂以及使用这种化合物治疗癌症的方法。
• [EN] BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1<br/>[FR] DÉRIVÉS DE BENZAMIDE POUR INHIBER L'ACTIVITÉ D'ABL1, D'ABL2 ET DE BCR-ABL2
  申请人：NOVARTIS AG

  公开号：WO2013171640A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式(I)的化合物：其中Y、Y、R、R 2、R 3和R 4在发明摘要中有定义；能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括含有这种化合物的药物制剂以及使用这种化合物治疗癌症的方法。
• Synthesis, molecular docking studies, and larvicidal activity evaluation of new fluorinated neonicotinoids against Anopheles darlingi larvae
  作者：Rochelly da Silva Mesquita、Andrii Kyrylchuk、Iryna Grafova、Denys Kliukovskyi、Andriy Bezdudnyy、Alexander Rozhenko、Wanderli Pedro Tadei、Markku Leskelä、Andriy Grafov

  DOI：10.1371/journal.pone.0227811

  日期：——

  docking. Their insecticide activity was tested on Anopheles larvae collected in suburban area of Manaus, Brazil. Four new fluorinated neonicotinoid analogs were prepared and tested against 3rd instars larvae of A. darlingi showing high larvicidal activity. Docking studies reveal binding modes of the synthesized compounds and suggest that their insecticidal potency is governed by specific interactions with

  达林按蚊是巴西疟疾的主要传播媒介，其特点是高度嗜人性和内食性。吡虫啉、噻虫啉和啶虫脒是最广泛使用的新烟碱类杀虫剂。然而，它们对非目标昆虫产生不利影响。氟吡呋酮已作为非氟化新烟碱类杀虫剂的替代品上市。含有三氟乙酰基取代基的新烟碱类杀虫剂由于较高的疏水性和代谢稳定性而显示出更高的杀虫活性。我们合成了含有氟化受体基团的新型新烟碱类杀虫剂，并通过分子对接研究评估了它们与烟碱乙酰胆碱受体（nAChR）结合位点的相互作用，以评估它们对达林吉丽线虫的杀幼虫活性，并评估它们的户外光降解行为。制备了新烟碱类似物并通过核磁共振和质谱进行表征。通过时间依赖性密度泛函理论对合成的分子进行建模和分析，通过分子对接研究它们与 nAChR 的相互作用。他们的杀虫活性在巴西马瑙斯郊区收集的按蚊幼虫上进行了测试。制备了四种新的氟化新烟碱类似物，并针对达林吉亚3龄幼虫进行了测试，显示出高杀幼虫活性。对接研究揭示了合成化合物的
• HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
  申请人：An Haoyun

  公开号：US20090048271A1

  公开（公告）日：2009-02-19

  Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a heteroaryl five-membered ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.

  本发明揭示了具有融合的双环杂芳环系统，其中含有一个杂环五元环的杂环取代的新化合物。这些化合物可以抑制多种类型的癌细胞的生长，因此可用于治疗癌症。这些化合物的疗效是通过一种监测细胞生长/迁移的系统来证明的，该系统显示它们是癌细胞生长和/或迁移的有效抑制剂。此外，本发明的化合物已被证明能够停止体内肿瘤的生长，并减小体内肿瘤的大小。本发明还揭示了包含这些化合物的组合物以及使用这些化合物和组合物治疗癌症的方法。
• [EN] BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR INHIBER L'ACTIVITÉ D'ABL1, ABL2 ET BCR-ABL1
  申请人：NOVARTIS AG

  公开号：WO2013171639A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及公式（I）的化合物：其中Y、Y1、R1、R2、R3和R4在本发明概述中有定义；能够抑制BCR-ABL1及其突变体的活性。本发明还提供了一种制备本发明化合物的方法，包括这种化合物的制药制剂以及使用这种化合物治疗癌症的方法。